

THE POWERWAND™

UNDISPUTED
BEST IN CLASS



ZERO BSI



36,000
CATHETER-DAYS

BLOOD
DRAWABLE 
60-99%

COMPLETION
OF THERAPY 
79-97%

PATIENT
SATISFACTION 
98-100%

\$448k
ANNUAL SAVINGS IN ONE ICU
& 1-2 LIVES SAVED

\$531.5k
ANNUAL SAVINGS IN MAGNET®
RECOGNIZED TEACHING HOSPITAL

\$90
SAVINGS PER
INSERTION

PEER REVIEWED PUBLICATIONS¹**ANNALS OF PHARMACOTHERAPY 2019**

- ▼ ZERO bloodstream infections (BSIs) in 1005 catheter-days
- ▼ POWERWAND can be successfully used with OPAT patients
- ▼ No severe complications associated with the use of vancomycin

AJIC 2019

- ▼ For 2 years, ZERO infections were recorded with the POWERWAND – over 5,430 catheter-days
- ▼ POWERWAND is only vascular access device in hospital system to never be associated with an infection
- ▼ PICC placements reduced by 35%
- ▼ Estimated 10 CLABSIs avoided and 1 patient death

MEDICAL DEVICES: EVIDENCE AND RESEARCH 2018

- ▼ 5 times more bacteria were able to attach and grow on the control polyurethane material than on the POWERWAND (P=0.0020)
- ▼ The few bacteria that were able to attach to the POWERWAND catheter material had a 1.5 times greater likelihood of dying

JAVA 2017

- ▼ 5 years of data proving vancomycin (4mg/mL) can safely and cost-efficiently be administered through POWERWAND
- ▼ ZERO bloodstream infections (BSIs) in 8,145 catheter-days
- ▼ 2.7% total complication rate

JAVA 2015

- ▼ ZERO BSIs
- ▼ 88 – 100% reduction of central line bloodstream infections (CLABSI) in two hospitals
- ▼ 58% reduction in PICC placements
- ▼ Estimated \$531,570 in annual savings

INFECTIOUS DISEASES IN CLINICAL PRACTICE 2015

- ▼ ZERO BSIs for 12 months (3.32 CLABSIs rate previously)
- ▼ 37% reduction in central line catheter days
- ▼ Translates to \$448,000 annual savings and 1-2 lives saved

JOURNAL OF VASCULAR ACCESS 2014

- ▼ POWERWANDs effectively replace PICCs for administration of short term vancomycin
- ▼ ZERO BSIs
- ▼ ZERO phlebitis
- ▼ ZERO thrombosis
- ▼ \$90.00 savings per insertion

JAVA 2012

- ▼ ZERO BSIs
- ▼ 88.5% completion of therapy (note: PICCs = 72-73%)
- ▼ Patient Satisfaction – 98%
- ▼ Average catheter dwell time – 6.8 days

SCIENTIFIC POSTERS¹**INS ANNUAL SCIENTIFIC MEETING 2016**

- ▼ POWERWAND safe for long-term administration of vancomycin (4mg/mL)
- ▼ ZERO BSIs in 264 catheter-days
- ▼ 8.3% complication rate

AMERICAN BURN ASSOCIATION NATIONAL CONFERENCE 2014

- ▼ POWERWAND reduced PIV sticks and supply costs
- ▼ Decreased nursing time (3.5 – 5.3 hours per patient)
- ▼ ZERO BSIs
- ▼ Patient Satisfaction – 100%
- ▼ Average catheter dwell time – 8.8 days

INS ANNUAL SCIENTIFIC MEETING 2013 (2 POSTERS)

- ▼ ZERO BSIs in 8,426 catheter-days
- ▼ 93% completion of therapy
- ▼ 99% full length of stay blood draw (occasionally used Cath-Flo™ off-label)
- ▼ ZERO BSIs in 617 catheter-days
- ▼ 87.5% completion of therapy
- ▼ 68% Blood draw

AVA ANNUAL SCIENTIFIC MEETING 2012 (2 POSTERS)

- ▼ ZERO BSIs in 477 catheter-days
- ▼ 97% completion of therapy
- ▼ 60% Blood draw for full length of stay
- ▼ ZERO BSIs in 624 catheter-days
- ▼ 84% full length of stay blood draw (used heparin lock)